- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07301255
ENV-294 voor matige tot ernstige astma: Een 12-weken durende studie bij volwassenen
Een fase 2, gerandomiseerd, dubbelblind, placebo-gecontroleerd, parallelgroep, 12 weken durende studie om de werkzaamheid, veiligheid en farmacokinetiek van ENV-294 te evalueren bij volwassen deelnemers met matig tot ernstig astma
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Clinical Operations
- E-mail: env-294.clinicaltrials@enveda.com
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35209
- Werving
- Enveda Investigative Site
-
-
California
-
Los Angeles, California, Verenigde Staten, 90025
- Werving
- Enveda Investigative Site
-
San Jose, California, Verenigde Staten, 95117
- Werving
- Enveda Investigative Site
-
West Hills, California, Verenigde Staten, 91307
- Werving
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs, Colorado, Verenigde Staten, 80907
- Werving
- Enveda Investigative Site
-
-
Florida
-
Hialeah, Florida, Verenigde Staten, 33012
- Werving
- Enveda Investigative Site
-
Miami, Florida, Verenigde Staten, 33135
- Werving
- Enveda Investigative Site
-
-
Georgia
-
Albany, Georgia, Verenigde Staten, 31707
- Werving
- Enveda Investigative Site
-
-
Illinois
-
Maryville, Illinois, Verenigde Staten, 62062
- Werving
- Enveda Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro, Kentucky, Verenigde Staten, 42301
- Werving
- Enveda Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Enveda Investigative Site
-
-
Michigan
-
Southfield, Michigan, Verenigde Staten, 48075
- Werving
- Enveda Investigative Site
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63141
- Werving
- Enveda Investigative Site
-
-
New York
-
The Bronx, New York, Verenigde Staten, 10455
- Werving
- Enveda Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Verenigde Staten, 97015
- Werving
- Enveda Investigative Site
-
Medford, Oregon, Verenigde Staten, 97504
- Werving
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Verenigde Staten, 29406
- Werving
- Enveda Investigative Site
-
-
Texas
-
McKinney, Texas, Verenigde Staten, 75069
- Werving
- Enveda Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- Werving
- Enveda Investigative Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
Placebo-vergelijker: Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence and Severity of Adverse Events
Tijdsspanne: From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Loss of Asthma Control Events
Tijdsspanne: Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
Tijdsspanne: Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tijdsspanne: Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tijdsspanne: Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tijdsspanne: Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
Tijdsspanne: Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ENV-294-211
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .